newsfilter
← Latest News
GlobeNewswire·

NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach

NTHI
  • NeOnc Technologies Holdings presented updated findings for investigational brain cancer programs NEO100 & NEO212 at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia.
  • NEO100 Phase 2a data showed 48.9% six-month progression-free survival in recurrent IDH1-mutant astrocytoma, surpassing the 20% historical benchmark, with median overall survival of 26.1 months.
  • The NEO100 program reported no treatment-related Grade 3 or higher adverse events & supports advancement toward an accelerated approval pathway.
  • A compassionate-use case involved a three-year-old boy in Abu Dhabi who began breathing independently & moving legs after receiving NEO100.
  • NEO212, an oral combination of temozolomide & perillyl alcohol, completed Phase 1 dose escalation with no observed myelosuppression & two objective responses lasting over 20 months.
  • FDA Type B End-of-Phase meeting for NEO100 is scheduled for early January 2027 to discuss a potential Phase 3 trial (NEO100-012) comparing the drug to investigator's-choice chemotherapy.
  • NEO212 has an FDA End-of-Phase 1 Type B meeting scheduled for November 23, 2026, to define Phase 2 design & patient populations.
  • CEO Amir Heshmatpour purchased 80,000 shares for approximately $333,100 between November 9–11, 2026, increasing his direct holdings to 3,333,000 shares.
  • CMO Thomas C. Chen purchased 5,016 shares for approximately $20,000, bringing total reported 2026 insider purchases to roughly 341,000 shares.
  • Analyst ratings include four Buy recommendations with price targets ranging from $13 to $20, while short interest exceeded 920,000 shares as of October 30.
  • NeOnc signed a memorandum of understanding with the Department of Health – Abu Dhabi to expand CNS oncology research, clinical collaboration, & real-world evidence generation.
Company
24/7 Market News and NeOnc Technology
Keywords
Nasdaq:NTHI, 24/7 Market News and NeOnc Technology, $NTHI, cancer, FDA, Phase 3, Fast Track